Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure

The advent of disease modifying therapies (DMT) in the past two decades has been the cornerstone of successful clinical management of multiple sclerosis (MS). Despite the great strides made in reducing the relapse frequency and occurrence of new signal changes on neuroimaging in patients with relaps...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Navid Manouchehri, Victor H. Salinas, Negar Rabi Yeganeh, David Pitt, Rehana Z. Hussain, Olaf Stuve
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2022-03-01
Rangatū:	Frontiers in Neurology
Ngā marau:	adaptive immunity innate immunity multiple sclerosis immunosenescence progressive multiple sclerosis disease modifying therapies
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fneur.2022.854390/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!